Actively Recruiting

Phase Not Applicable
Age: 1Minute - 6Months
All Genders
ID06822400

A Multi-center, Randomized, Controlled Investigation of Tetralogy of Fallot in Neonates

Led by Beijing Anzhen Hospital · Updated on 2025-09-10

160

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

B

Beijing Anzhen Hospital

Lead Sponsor

C

Children's Hospital of Fudan University

Collaborating Sponsor

AI-Summary

What this Trial Is About

Child health is essential for overall public health, and neonatal mortality is a key indicator of a nation's health standards. In China, congenital heart disease (CHD) is the most common birth defect, with about 70,000-80,000 newborns affected yearly, including nearly 10,000 with critical congenital heart disease (CCHD). Tetralogy of Fallot (TOF), a major form of CCHD, causes serious heart defects that lead to low oxygen levels and life-threatening symptoms, requiring surgical repair to improve survival and quality of life. Despite advances, long-term outcomes after TOF surgery still present challenges, especially related to preserving pulmonary valve function and reducing heart rhythm problems.

CONDITIONS

Brief Title

Investigation of Tetralogy of Fallot in Neonates

Who Can Participate

Age: 1Minute - 6Months
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Clinical diagnosis of Tetralogy of Fallot
  • Full-term neonates aged 28 days or less
  • Birth weight greater than 2.5 kilograms
  • Male or female patients
  • Ability to provide informed consent
Not Eligible

You will not qualify if you...

  • Preterm infants
  • Presence of complex cardiac anomalies
  • Severe Tetralogy of Fallot with pulmonary artery underdevelopment or recurring low oxygen episodes
  • Conditions requiring palliative or single-ventricle repair
  • Genetic or chromosomal abnormalities
  • Neonatal bronchopulmonary dysplasia
  • Worsening condition preventing surgery by 3 months of age in the control group
  • Parental refusal to participate in the trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surgery and Immediate Post-operative Care

Duration - Up to 30 days

Participants undergo corrective surgery for Tetralogy of Fallot either within 28 days of birth or between 3-6 months of age, followed by immediate post-operative care.

Approximately 6 post-operative visits

Post-operative Follow-up

Duration - Up to 3 years

Participants are monitored for surgical complications, cardiac related indicators, and other follow-up assessments after surgery.

Regular follow-up visits over 3 years

Trial Site Locations

Total: 1 location

1

Beijing Anzhen Hospital

Beijing, Beijing Municipality, China, 100013

Actively Recruiting

Loading map...

Research Team

Q

Qiang Wang Prof Beijing Anzhen Hospital,Capital Medical University

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Multimodal Clinical Data Integration and Artificial Intellig...

Congenital Heart Disease (CHD)

Actively Recruiting

1 location

Adult Congenital Heart Disease International EValuation of t...

Adult Congenital Heart Disease

Actively Recruiting

11 locations

Clinical Study of an Integrated Prenatal and Postnatal Treat...

Congenital Heart Disease

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here